• br Methods br Results br

  2023-08-11

  

  Methods Results Discussion Acknowledgements This work was supported by the National Institutes of Health [Grant R21 NS081429], a Pilot Grant from the Vanderbilt Conte Center supported by the National Institutes of Health [Grant P50 M096972], and by the Department of Anesthesiology at V

• br Acknowledgements We thank Dr Stefan Schulte Merker and

  2023-08-11

  

  Acknowledgements We thank Dr. Stefan Schulte-Merker and his group members at the Hubrecht Institute (Utrecht, the Netherlands) for their invaluable support of the zebrafish studies. Our work is supported by grants from the Dutch Cancer Society (KWF) and the Netherlands Organisation for Scientific

• Nowadays more than kinases have

  2023-08-11

  

  Nowadays, more than 500 kinases have been identified of human genome [2]. Imatinib (Gleevec) was the first tyrosine kinase inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia [3], and kinases have become an attractive target for the developme

• Aminoglutethimide first generation aromatase inhibitor has

  2023-08-10

  

  Aminoglutethimide, first generation aromatase inhibitor, has been tried as an antiepileptic drug in combination with other standard drugs (Aguilar et al., 1961). Letrozole is a third generation reversible non-steroidal aromatase inhibitor, approved by US-FDA, for the treatment of postmenopausal wom

• Dopaminergic neurons are vulnerable to oxidative products an

  2023-08-10

  

  Dopaminergic neurons are vulnerable to oxidative products and inflammatory responses; these processes may play important roles in the etiology of PD. Because glial gonadotropin releasing hormone agonist are the main generators of inflammatory responses in the CNS, the possibility that PD results fro

• At Johns Hopkins Aramco Health JHAH we started an ASP

  2023-08-10

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• The habit of prescribing antibiotics just

  2023-08-10

  

  The habit of prescribing cerk “just-in-case” there is an infection is based on the misguided perception that antibiotics are “safe” drugs and therefore pose little risk to patients. Surgeons need to dispel this myth. In the outpatient setting, antibiotic-associated ADEs account for 19% of all emerg

• Complementing the effects of ARB and ACEI on HDL

  2023-08-10

  

  Complementing the effects of ARB and ACEI on HDL capacity to elicit cholesterol efflux, HDL of ARB- and ACEI-treated groups significantly lessened macrophage production of superoxide (Fig 2). As with efflux, there was no difference in this effect between the ARB and ACEI groups. These data are inter

• However in recent years advanced

  2023-08-10

  

  However, in recent years advanced experiments and findings are emerging to give us more detailed information on Aβ-membrane interactions. Several reviews have provided background on the fibrillation of Aβ and the Aβ-membrane interactions [[18], [19], [20], [21], [22]]. In this review, we mainly focu

• br Discussion Hepatic dysfunction in the metabolic

  2023-08-10

  

  Discussion Hepatic dysfunction in the metabolic syndrome is a driver of negative patient outcomes that requires more therapeutic options. The complexity of liver alterations in this disease – elevated de novo synthesis of fatty acids and cholesterol, reduced clearance of circulating atherogenic L

• br Experimental section br Abbreviations PSA puromycin sensi

  2023-08-10

  

  Experimental section Abbreviations PSA, puromycin–sensitive aminopeptidase; APN, aminopeptidase N; AML, acute myeloid Leukemia; ALL, acute lymphoblastic leukemia; AADR, amino BAN ORL 24 deprivation response; PAN, puromycin aminonucleoside; DCC, dicyclohexyl carbodiimide; NHS, N–hydroxy succin

• glucose transporter When arachidonic acid is used as

  2023-08-10

  

  When arachidonic glucose transporter is used as a substrate, the platelet-type 12S-lipoxygenase produces predominantly the 12S-hydroperoxy derivative. In contrast, the leukocyte-type 12S-lipoxygenases generate substantial amounts of the 15-lipoxygenase product in addition to the 12S-hydroperoxy der

• One of the specifications of the NIA AA

  2023-08-10

  

  One of the specifications of the NIA-AA research framework was that it ONC201 be applicable in two distinct research contexts—interventional trials and observational research. In many if not most modern AD interventional trials, individuals are selected for inclusion with the aid of biomarkers. The

• An ALK rearrangement was found in

  2023-08-10

  

  An ALK rearrangement was found in all the analyzable ‘truly positive’ IHC+/FISH+ samples, and the proportion of the various transcripts was in accordance with the literature [[26], [46], [47], [48]]. In these samples, the RNA-seq technique was therefore 100% sensitive and specific. Additional non-ta

• ppy br Downstream signalling of AKT A consensus

  2023-08-10

  

  Downstream signalling of AKT A consensus phosphorylation motif has been described for AKT substrates: R-X-R-X-X-S/T-B where X represents any amino ppy and B represents bulky hydrophobic residues (Alessi, Caudwell, Andjelkovic, Hemmings, & Cohen, 1996). Numerous AKT substrates have been published

16099 records 301/1074 page Previous Next First page 上5页 301302303304305 下5页 Last page